Fueling inflammation at tumor microenvironment: The role of multiligand/rage axis

Carcinogenesis

Volumn 31, Issue 3, 2010, Pages 334-341

  Rojas, Armando ^a   Figueroa, Hector ^a   Morales, Erik ^a  

^a UNIVERSIDAD CATÓLICA DEL MAULE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE; TOLL LIKE RECEPTOR; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; ANTIGEN T CELL RECEPTOR, ZETA CHAIN; IMMUNOGLOBULIN RECEPTOR; LIGAND; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR PROTEIN;

APOPTOSIS; CANCER INVASION; CARCINOGENESIS; CELL HYPOXIA; CELL INTERACTION; GENETIC POLYMORPHISM; HUMAN; INFLAMMATION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TUMOR IMMUNOLOGY; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANIMAL; AUTOCRINE EFFECT; BIOLOGICAL MODEL; CHEMISTRY; DIET; DISEASE COURSE; GENETICS; GLYCOLYSIS; IMMUNOLOGY; MOUSE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PARACRINE SIGNALING; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION;

ANIMALS; AUTOCRINE COMMUNICATION; CELL HYPOXIA; DIET; DISEASE PROGRESSION; GLYCOLYSIS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; LIGANDS; MICE; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PARACRINE COMMUNICATION; RECEPTOR CROSS-TALK; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION;

EID: 77950898092     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp322     Document Type: Review

References (125)

1. Blakwill, F. et al. (2001) Inflammation and cancer: back to Virchow? Lancet, 237, 539-545.
2. Mantovani, A. et al. (2008) Cancer-related inflammation. Nature, 454, 436-444.
3. Rakoff-Nahoum, S. et al. (2009) Toll-like receptors and cancer. Nat. Rev. Cancer, 9, 57-63.
4. zur Hausen, H. (2006) Infections Causing Human Cancer. Wiley-VCH, Weinheim, Germany.
5. McNamara, D. et al. (2008) Helicobacter pylori infection and the pathogenesis of gastric cancer: a paradigm for host-bacterial interactions. Dig. Liver Dis., 40, 504-509.
6. Elkahwaji, J.E. et al. (2007) Chronic bacterial infection and inflammation incite reactive hyperplasia in a mouse model of chronic prostatitis. Prostate, 67, 14-21.
7. Herszenyi, L. et al. (2007) Carcinogenesis in inflammatory bowel disease. Dig. Dis., 25, 267-269.
8. Tazuma, S. et al. (2001) Carcinogenesis of malignant lesions of the gall bladder. The impact of chronic inflammation and gallstones. Langenbecks Arch. Surg., 386, 224-229.
9. Kuniyasu, H. et al. (2002) Expression of receptor fro advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J. Pathol., 196, 163-170.
10. Kaniyasu, H. et al. (2003) Co-expression of receptor for advanced glycation end-products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol. Rep., 10, 445-448.
11. Hirata, K. et al. (2003) Expression of receptor for advanced glycation end products (RAGE) in human biliary cancer cells. Hepatogastroenterology, 50, 1205-1207.
12. Hirata, K. et al. (2001) Differential expression of RAGE in human pancreatic carcinoma cells. Hepatogastroenterology, 48, 1577-1578.
13. Ishiguro, H. et al. (2005) Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate, 64, 92-100.
14. Bhawal, U.K. et al. (2005) Association of expression of receptor for advanced glycation end products and invasive activity of oral squamous cell carcinoma. Oncology, 69, 246-255.
15. Bartling, B. et al. (2005) Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis, 26, 293-301.
16. Bartling, B. et al. (2006) Proliferative stimulus of lung fibroblasts on lung cancer cells is impaired by the receptor for advanced glycation endproducts. Am. J. Respir. Cell. Mol. Biol., 34, 83-91.
17. Basta, G. (2008) Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis, 19, 9-21.
18. Schmidt, A.M. et al. (1992) Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem., 267, 14987-14997.
19. Yan, S.F. et al. (2008) Mechanisms of disease: advanced glycation endproducts and their receptor in inflammation and diabetes complications. Nat. Clin. Pract. Endocrinol. Metab., 4, 285-293.
20. Rojas, A. et al. (2008) Advanced Glycation and ROS: a link between diabetes and heart failure. Curr. Vasc. Pharmacol., 6, 44-51.
21. Schmidt, A.M. et al. (2001) Receptor for AGE (RAGE) is a gene within the major histocompatibility class III region: implications for host response mechanisms in homeostasis and chronic disease. Front. Biosci., 6, D1151-D1160.
22. Sugaya, K. et al. (1994) Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3. Genomics, 23, 408-419.
23. Schmidt, A.M. et al. (2001) The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest., 108, 949-955.
24. Neeper, M. et al. (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem., 267, 14998-15004.
25. Xie, J. et al. (2001) Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J. Biol. Chem., 283, 27255-27269.
26. Srikrishna, G. et al. (2002) N -Glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth. J Neurochem., 80, 998-1008.
27. Hudson, B.I. et al. (2008) Identification, classification, and expression of RAGE gene splice variants. FASEB J., 22, 1572-1580.
28. Geroldi, D. et al. (2006) Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr. Med. Chem., 13, 1971-1978.
29. Kislinger, T. et al. (1999) N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem., 274, 31740-31749.
30. Cho, S.J. et al. (2007) The road to advanced glycation end products: a mechanistic perspective. Curr. Med. Chem., 14, 1653-1671.
31. van Heijst, J.W. et al. (2005) Advanced glycation end products in human cancer tissues: detection of Nepsilon-(carboxymethyl)lysine and argpyrimidine. Ann. N. Y. Acad. Sci., 1043, 725-733.
32. Chuyen, N. (2006) Toxicity of the AGEs generated from the Maillard reaction: on the relationship of food-AGEs and biological-AGEs. Mol. Nutr. Food Res., 50, 1140-1149.
33. Yan, S.D. et al. (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature, 382, 685-691.
34. Yan, S.D. et al. (2000) Receptor dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat. Med., 6, 643-651.
35. Marenholz, I. et al. (2004) S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem. Biophys. Res. Commun., 322, 1111-1122.
36. Lotze, M.T. et al. (2005) High mobility group box-1 protein (HMGB1): nuclear weapon indamage-associated molecular pattern the immune arsenal. Nat. Rev. Immunol., 5, 331-342.
37. Coffelt, S.B. et al. (2008) Tumors sound the alarmin(s). Cancer Res., 68, 6482-6485.
38. Salama, I. et al. (2008) A review of the S100 proteins in cancer. Eur. J. Surg. Oncol., 34, 357-364.
39. Campana, L. et al. (2008) HMGB1: a two-headed signal regulating tumor progression and immunity. Curr. Opin. Immunol., 20, 518-523.
40. Gebhardt, C. et al. (2008) RAGE signaling sustains inflammation and promotes tumor development. J. Exp. Med., 205, 275-285.
41. Turovskaya, O. et al. (2008) RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis, 29, 2035-2043.
42. Huang, J. et al. (2001) Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J. Cell. Biochem., 81, 102-113.
43. Yeh, C. et al. (2001) Requirement for p38 and p44/42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kB transcriptional activation and cytokine secretion. Diabetes, 50, 1495-1504.
44. Huttunen, H. et al. (2002) RAGE signaling induces CREB-dependent chromogranin expression during neuronal differentiation. J. Biol. Chem., 277, 38635-38646.
45. Sethi, G. et al. (2008) Nuclear factor-kappaB activation: from bench to bedside. Exp. Biol. Med., 233, 21-31.
46. Kundu, J.K. et al. (2008) Inflammation: gearing the journey to cancer. Mutat. Res., 659, 15-30.
47. Garlanda, C. et al. (2004) Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc. Natl Acad. Sci. USA, 101, 3522-3526.
48. Subarsky, P. et al. (2003) The hypoxic tumour microenvironment and metastatic progression. Clin. Exp. Metastasis, 20, 237-250.
49. Rius, J. et al. (2008) NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature, 453, 807-811.
50. Hiwatashi, K. et al. (2008) A novel function of the receptor for advanced glycation end-products (RAGE) in association with tumorigenesis and tumor differentiation of HCC. Ann. Surg. Oncol., 15, 923-933.
51. Schioppa, T. et al. (2003) Regulation of the chemokine receptor CXCR4 by hypoxia. J. Exp. Med., 198, 1391-1402.
52. de Bruin, E.C. (2008) Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treat. Rev., 34, 737-749.
53. Miki, S. et al. (1993) Expression of receptors for advanced glycosylation end products on renal cell carcinoma cells in vitro. Biochem. Biophys. Res. Commun., 196, 984-989.
54. Zhu, Z. et al. (2001) Anoikis and metastatic potential of cloudman S91 melanoma cells. Cancer Res., 61, 1707-1716.
55. Hsieh, H.L. et al. (2003) Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochem. Biophys. Res. Commun., 307, 375-381.
56. Arumugam, T. et al. (2005) S100P promotes pancreatic cancer growth, survival, and invasion. Clin. Cancer Res., 11, 5356-5364.
57. Kang, R. et al. (2009) The receptor of advanced glycation end-products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ. Advance online publication 16 October 2009, doi: 10.1038/cdd.2009.149.
58. Chen, K. et al. (2007) Toll-like receptors in inflammation, infection and cancer. Int. Immunopharmacol., 7, 1271-1285.
59. Killeen, S.D. et al. (2006) Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword? Br. J. Cancer, 95, 247-252.
60. Huang, B. et al. (2005) Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res., 65, 5009-5014.
61. Bierhaus, A. et al. (2005) Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med., 83, 876-886.
62. Ostendorp, T. et al. (2007) Structural and functional insights into RAGE activation by multimeric S100B. EMBO J., 26, 3868-3878.
63. Hu, X. et al. (2004) Multimerization and interaction of Toll and Spatzle in Drosophila. Proc. Natl Acad. Sci. USA, 101, 9369-9374.
64. de Bouteiller, O. et al. (2005) Recognition of double-stranded RNA by human toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH. J. Biol. Chem., 280, 38133-38145.
65. van Beijnum, J.R. et al. (2008) Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis, 11, 91-99.
66. Lin, L. (2006) RAGE on the Toll Road? Cell. Mol. Immunol., 3, 351-358.
67. Swann, J.B. et al. (2008) Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc. Natl Acad. Sci. USA, 105, 652-656.
68. Tian, J. et al. (2007) Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol., 8, 487-496.
69. Derniame, S. et al. (2008) Alteration of the immunological synapse in lung cancer: a microenvironmental approach. Clin. Exp. Immunol., 154, 48-55.
70. Whiteside, T.L. (2003) Down-regulation of ς-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol. Immunother., 53, 865-878.
71. Serafini, P. et al. (2004) Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother., 53, 64-72.
72. Baniyash, M. (2004) TCR ς chain downregulation: curtaining excessive inflammatory immune response. Nat. Rev. Immunol., 4, 675-687.
73. Bunt, S.K. et al. (2007) Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res., 67, 10019-10026.
74. Sinha, P. et al. (2008) S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J. Immunol., 181, 4666-4675.
75. Price, C.L. et al. (2004) Advanced glycation end products modulate the maturation and function of peripheral blood dendritic cells. Diabetes, 53, 1452-1458.
76. Dumitriu, I.E. et al. (2005) Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. Eur. J. Immunol., 35, 2184-2190.
77. Dumitriu, I.E. et al. (2005) Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J. Immunol., 174, 7506-7515.
78. Shevach, E.M. (2000) Regulatory T cells in autoimmunity. Annu. Rev. Immunol., 18, 423-449.
79. Beyer, M. et al. (2009) Regulatory T cells: major players in tumor microenvironment. Curr. Pharm. Des., 15, 1879-1893.
80. Whiteside, T.L. (2008) The tumor microenvironment and its role in promoting tumor growth. Oncogene, 27, 5904-5912.
81. Chaput, N. et al. (2007) Regulatory T cells prevent CD8+ Tcellmaduration by inhibiting CD4+ Th cell at tumor sites. J. Immunol., 179, 4969-4978.
82. Huang, L.F. et al. (2009) The effect of high-mobility group box 1 protein on activity of regulatory T cell after thermal injury in rats. Shock, 31, 322-329.
83. Greenhough, A. et al. (2009) The COX-2/PGE2 pathway: a key role in the hallmarks of cancer and adaptation to the tumor microenvironment. Carcinogenesis, 30, 277-386.
84. Sinha, P. et al. (2007) Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res., 67, 4507-4513.
85. Sharma, S. et al. (2005) Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res., 65, 5211-5220.
86. Baratelli, F. et al. (2005) Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+T cells. J. Immunol., 175, 1483-1490.
87. Lee, S.Y. et al. (2009) The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells. J. Immunother., 32, 22-28.
88. Katz, J.B. et al. (2008) Indoleamine 2, 3-dioxygenase in T-cell tolerance and tumoral immune scape. Immunol. Rev., 222, 206-221.
89. Shanmugam, N. et al. (2008) Distinct roles of heterogenous nuclear ribonuclear protein K and microRNA-16 in cycloxigenase-2 RNA stability induced by S100b, a ligand of the receptor of advanced glycation end products. J. Biol. Chem., 283, 36221-36233.
90. Hughes, C.C. (2008) Endothelial-stromal interactions in angiogenesis. Curr. Opin. Hematol., 15, 204-209.
91. Bhat, T.A. et al. (2008) Tumor angiogenesis-a potential target in cancer chemoprevention. Food Chem. Toxicol., 46, 1334-1345.
92. Nyberg, P. et al. (2008) Tumor microenvironment and angiogenesis. Front. Biosci., 13, 6537-6553.
93. Hoffmann, S. et al. (2002) Advanced glycation end products induce choroidal endothelial cell proliferation, matrix metalloproteinase-2 and VEGF upregulation in vitro. Graefes Arch. Clin. Exp. Ophthalmol., 240, 996-1002.
94. Otero, K. et al. (2001) Albumin-derived advanced glycation end-products trigger the disruption of the vascular endothelial cadherin complex in cultured human and murine endothelial cells. Biochem. J., 359, 567-574.
95. Yamagishi, S. et al. (1997) Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J. Biol. Chem., 272, 8723-8730.
96. Rojas, A. et al. (2004) Advanced glycation and endothelial functions: a link towards vascular complications in diabetes. Life Sci., 76, 715-730.
97. Ding, Y.T. et al. (2008) The role of endothelial progenitor cells in tumour vasculogenesis. Pathobiology, 75, 265-273.
98. Chavakis, E. et al. (2007) High-mobility group box 1 activates integrindependent homing of endothelial progenitor cells. Circ. Res., 100, 204-212.
99. Wakisaka, N. et al. (2003) Epstein-Barr virus induces invasion and metastasis factors. Anticancer Res., 23, 2133-2138.
100. Tsuji, A. et al. (2008) Induction of receptor for advanced glycation end products by EBV latent membrane protein 1 and its correlation with angiogenesis and cervical lymph node metastasis in nasopharyngeal carcinoma. Clin. Cancer Res., 14, 5368-5375.
101. Yang, L. et al. (2004) Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell, 6, 409-421.
102. Condeelis, J. et al. (2006) Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell, 124, 263-266.
103. Sica, A. et al. (2008) Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett., 267, 204-215.
104. Mantovani, A. et al. (2002) Macrophage polarization: tumor associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol., 23, 549-555.
105. Allavena, P. et al. (2008) The inflammatory microenviroment in tumor progression: the role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol., 66, 1-9.
106. Webster, L. et al. (1997) Induction of TNFand IL-1β mRNA in monocytes by methylglyoxal and advanced glycated end product-modified human serum albumin. Biochem. Soc. Trans., 25, 250S.
107. Rashid, G. et al. (2006) Advanced glycation end products stimulate tumor necrosis factor-alpha and interleukin-1 beta secretion by peritoneal macrophages in patients on continuous ambulatory peritoneal dialysis. Isr. Med. Assoc. J., 8, 36-39.
108. Wink, D.A. et al. (1998) The multifaceted roles of nitric oxide in cancer. Carcinogenesis, 19, 711-721.
109. Wei, D. et al. (2003) Direct demonstration of negative regulation of tumor growth and metastasis by host-inducible nitric oxide synthase. Cancer Res., 63, 3855-3859.
110. Sumi, D. et al. (2004) Regulation of inducible nitric oxide synthase expression in advanced glycation end product-stimulated raw 264.7 cells: the role of heme oxygenase-1 and endogenous nitric oxide. Diabetes, 53, 1841-1850.
111. Rojas, A. et al. (1996) Effect of advanced glycosylation end products on the induction of nitric oxide synthase in murine macrophages. Biochem. Biophys. Res. Commun., 225, 358-362.
112. Decker, N.K. et al. (2008) Nitric oxide regulates tumor cell cross-talk with stromal cells in the tumor microenvironment of the liver. Am. J. Pathol., 173, 1002-1012.
113. Xu, B. et al. (2005) Inhibition of human endothelial cell nitric oxide synthesis by advanced glycation end-products but not glucose: relevance to diabetes. Clin Sci (Lond), 109, 439-446.
114. Rojas, A. et al. (2000) Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products. Circ. Res., 86, E50-E54.
115. Bronte, V. et al. (2008) Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol., 5, 641-654.
116. Hori, O. et al. (1995) The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem., 270, 25752-25761.
117. Taguchi, A. et al. (2000) RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature, 405, 354-360.
118. Abe, R. et al. (2004) Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J. Invest. Dermatol., 122, 461-467.
119. Tateno, T. et al. (2009) Expression of receptor for advanced glycation end products (RAGE) is related to prognosis in patients with esophageal squamous cell carcinoma. Ann. Surg. Oncol., 16, 440-446.
120. Jadeski, L.C. et al. (2003) NO-mediated promotion of mammary tumor cell migration requires sequential activation of nitric oxide synthase, guanilate cyclase and mitogen-activated protein kinase. Int. J. Cancer, 106, 496-504.
121. Shanmugam, N. et al. (2003) Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products. J. Biol. Chem., 278, 34834-34844.
122. Imyanitov, E.N. (2009) Gene polymorphisms, apoptotic capacity and cancer risk. Hum. Genet., 125, 239-246.
123. Whibley, C. et al. (2009) p53 polymorphisms: cancer implications. Nat. Rev. Cancer, 9, 95-107.
124. Gu, H. et al. (2008) Gly82Ser polymorphism of the receptor for advanced glycation end products is associated with an increased risk of gastric cancer in a Chinese population. Clin. Cancer Res., 14, 3627-3632.
125. Tesarová, P. et al. (2007) Receptor for advanced glycation end products (RAGE)-soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest., 25, 720-725.